arrow
N

Natalie Filmann

Goethe University Frankfurt
H指数:27
被引数:2,726

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validity, Accuracy, and Safety Assessment of an Aerobic Interval Training Using an App-Based Prehabilitation Program (PROTEGO MAXIMA Trial) Before MajorSurgery: Prospective, Interventional Pilot Study
2025-02-100
OAAI
Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial

RAD51与HER2阴性乳腺癌(BC)患者中同源重组缺陷(HRD)疗效结局的关联:GeparOla试验的事后分析

2024-09-010
PRE
Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial
2024-05-020
PRE
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
2024-05-010
PRE
Predictive value of a novel digital risk calculator to determine early patient outcomes after major surgery: a proof-of-concept pilot study

新型数字风险计算器在确定大手术后早期患者预后中的预测价值: 一项概念验证试点研究

2024-04-120
OAAI
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA)

激素受体阳性/HER2阴性转移性乳腺癌一线化疗后使用CDK4/6抑制剂瑞博西尼进行抗激素维持治疗: 一项II期试验 (AMICA)

BREAST
IF7.9
2023-12-014
OAAI
Treatment of Non-Anastomotic Biliary Strictures after Liver Transplantation: How Effective Is Our Current Treatment Strategy?
2023-05-163
OAAI
Evolution of synchronous female bilateral breast cancers and response to treatment
2023-03-068
OAAI
Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial

口腔癌的新辅助放化疗: 前瞻性反向试验的反应和中期分析的预测因素

2022-03-245
OAAI
Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium- Radiation Oncology Group (DKTK-ROG)
2022-02-0110
OAAI